Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data

Tomas Kauer - Moderator

Sep 10, 2024 - 18:00

Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data

Tags:

Previous Article

Rubrik stock shines with raised guidance and strong cloud growth

Morgan Stanley raises FCC Co stock outlook, targets 15% upside

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Tomas Kauer - Moderator

Related Posts

New York tech investor and serial entrepreneur Kevin Ryan explains when to sell your company

New York tech investor and serial entrepreneur Kevin Ry...

Tomas Kauer - Mode... Sep 30, 2024

23andMe’s future prompts more worries, as genomic data analysis improves

23andMe’s future prompts more worries, as genomic data ...

Tomas Kauer - Mode... Oct 6, 2024

The founders of SlideShare are making sharing docs more social with their new platform, Jaunt

The founders of SlideShare are making sharing docs more...

Tomas Kauer - Mode... Dec 12, 2024